JP2019523283A - 大麻組成物 - Google Patents

大麻組成物 Download PDF

Info

Publication number
JP2019523283A
JP2019523283A JP2019505171A JP2019505171A JP2019523283A JP 2019523283 A JP2019523283 A JP 2019523283A JP 2019505171 A JP2019505171 A JP 2019505171A JP 2019505171 A JP2019505171 A JP 2019505171A JP 2019523283 A JP2019523283 A JP 2019523283A
Authority
JP
Japan
Prior art keywords
weight
amount
extract
cannabis
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019505171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523283A5 (cg-RX-API-DMAC7.html
Inventor
カレリス、ハリー
ゴードン、マラ
スミス、スチュワート
ウォッシャー、スチュワート
Original Assignee
ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019523283(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド, ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド filed Critical ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
Publication of JP2019523283A publication Critical patent/JP2019523283A/ja
Publication of JP2019523283A5 publication Critical patent/JP2019523283A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2019505171A 2016-08-03 2017-08-03 大麻組成物 Pending JP2019523283A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
US62/370,304 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (2)

Publication Number Publication Date
JP2019523283A true JP2019523283A (ja) 2019-08-22
JP2019523283A5 JP2019523283A5 (cg-RX-API-DMAC7.html) 2020-01-23

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019505171A Pending JP2019523283A (ja) 2016-08-03 2017-08-03 大麻組成物

Country Status (15)

Country Link
US (2) US11779562B2 (cg-RX-API-DMAC7.html)
EP (1) EP3493798A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019523283A (cg-RX-API-DMAC7.html)
KR (2) KR20210013645A (cg-RX-API-DMAC7.html)
CN (1) CN109843287A (cg-RX-API-DMAC7.html)
AU (4) AU2017307643B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019001852A2 (cg-RX-API-DMAC7.html)
CA (1) CA3031810A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000270A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019001044A2 (cg-RX-API-DMAC7.html)
IL (2) IL296008B2 (cg-RX-API-DMAC7.html)
MX (1) MX386620B (cg-RX-API-DMAC7.html)
PE (1) PE20200726A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201900665VA (cg-RX-API-DMAC7.html)
WO (1) WO2018023163A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020524151A (ja) * 2017-06-19 2020-08-13 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 睡眠障害組成物及びその治療
JP2023535313A (ja) * 2020-07-15 2023-08-17 リネア・ソチエタ・アノニマ アサ（Ｃａｎｎａｂｉｓ ｓａｔｉｖａ）抽出物およびその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102447510B1 (ko) 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
KR20210013645A (ko) 2016-08-03 2021-02-04 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018183115A1 (en) * 2017-03-30 2018-10-04 Ojai Energetics Pbc Methods and compositions for enhancing health
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
US20210251949A1 (en) * 2018-06-15 2021-08-19 California Cannabinoids Compositions and Methods for Treatment of Narcolepsy and Related Disorders
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
US12011471B2 (en) * 2019-12-19 2024-06-18 Atlas365 Incorporated Extracts enriched with polyphenolic compounds and related methods
US11000818B1 (en) * 2019-12-27 2021-05-11 Cresco Labs Llc Post processing method for cannabis oil
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005272388A (ja) * 2004-03-25 2005-10-06 Ss Pharmaceut Co Ltd 睡眠改善医薬組成物
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2016064987A1 (en) * 2014-10-21 2016-04-28 United Cannabis Corp. Cannabis extracts and methods of preparing and using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400319B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
CN104619318A (zh) 2012-05-03 2015-05-13 回音制药公司 含有δ9-四氢大麻酚的大麻植物分离物及其制备方法
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
WO2014145490A2 (en) * 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
HRP20191097T1 (hr) * 2013-10-29 2019-09-20 Biotech Institute, Llc Uzgoj, proizvodnja, obrada i upotreba specijalnog kanabisa
RU2016129536A (ru) 2013-10-31 2018-01-31 Фулл Спектрум Лабораториз, Лтд. Препараты на основе терпенов и каннабиноидов
WO2015200049A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
ES2877361T3 (es) 2014-06-27 2021-11-16 Farm To Farma Inc Formulaciones de cannabinoides bucales y sublinguales y método para hacer las mismas
US11793769B2 (en) * 2014-08-25 2023-10-24 Jai Shankar Sukul Device with compositions for delivery to the lungs, the oral mucosa and the brain
AU2015360349B2 (en) 2014-12-12 2020-10-08 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
EP3250200A4 (en) 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3493799A4 (en) 2016-08-03 2020-04-01 Zelda Therapeutics Operations Pty Ltd CANNABIS
KR20210013645A (ko) 2016-08-03 2021-02-04 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
KR102447510B1 (ko) 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
CN110944632A (zh) 2017-06-19 2020-03-31 塞尔达治疗手术有限公司 睡眠障碍组合物及其治疗
US20200276155A1 (en) 2017-09-15 2020-09-03 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
MX2022015799A (es) 2020-06-12 2023-04-11 Zelira Therapeutics Operations Pty Ltd Composicion y metodo para el tratamiento del dolor cronico.
MX2023005339A (es) 2020-11-06 2023-05-22 Zelira Therapeutics Operations Pty Ltd Tecnologia de encapsulacion de cannabinoides.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005272388A (ja) * 2004-03-25 2005-10-06 Ss Pharmaceut Co Ltd 睡眠改善医薬組成物
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2016064987A1 (en) * 2014-10-21 2016-04-28 United Cannabis Corp. Cannabis extracts and methods of preparing and using same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020524151A (ja) * 2017-06-19 2020-08-13 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 睡眠障害組成物及びその治療
JP2023535313A (ja) * 2020-07-15 2023-08-17 リネア・ソチエタ・アノニマ アサ（Ｃａｎｎａｂｉｓ ｓａｔｉｖａ）抽出物およびその使用

Also Published As

Publication number Publication date
IL296008B2 (en) 2024-09-01
PE20200726A1 (es) 2020-07-21
EP3493798A4 (en) 2020-05-06
EP3493798A1 (en) 2019-06-12
AU2018100923C4 (en) 2019-10-31
CL2019000270A1 (es) 2019-10-04
SG11201900665VA (en) 2019-02-27
MX2019001285A (es) 2019-06-13
AU2019253841B2 (en) 2021-07-01
US20230414559A1 (en) 2023-12-28
IL264461A (en) 2019-02-28
KR20190035791A (ko) 2019-04-03
WO2018023163A1 (en) 2018-02-08
CN109843287A (zh) 2019-06-04
AU2019253841A1 (en) 2019-11-14
KR20210013645A (ko) 2021-02-04
US20220347155A1 (en) 2022-11-03
US12239628B2 (en) 2025-03-04
AU2018100923B4 (en) 2018-09-27
AU2021240297A1 (en) 2021-10-28
AU2017307643B2 (en) 2019-07-25
US11779562B2 (en) 2023-10-10
IL296008B1 (en) 2024-05-01
BR112019001852A2 (pt) 2019-05-07
IL264461B2 (en) 2024-09-01
MX386620B (es) 2025-03-19
IL296008A (en) 2022-10-01
AU2018100923A4 (en) 2018-08-09
CA3031810A1 (en) 2018-02-08
CO2019001044A2 (es) 2019-04-30
AU2021240297B2 (en) 2023-08-24
IL264461B1 (en) 2024-05-01
AU2017307643A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
US12239628B2 (en) Cannabis composition
US12239680B2 (en) Sleep disorder compositions and treatments thereof
JP7139559B2 (ja) 大麻組成物
AU2018101357A4 (en) Composition and method for treating autism
US20210308092A1 (en) Cannabinoid composition and method for treating ptsd and/or anxiety
NZ789786A (en) Sleep Disorder Compositions and Treatments Thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191205

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191205

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200623